Clinical Research Directory

Inclusion Criteria: 1. Age 18 and above 2. Diagnosis of membranous nephropathy PLA2R1 antibodies-mediated 3. Immunological relapse (defined as an increase in anti-PLA2R1 antibody titer \> 14 RU/mL after a phase of anti-PLA2R1 antibody negativation, i.e. immunological remission) 4. Plasma IL-17A levels \> 73 pg/mL after non-specific stimulation of peripheral blood immune cells 5. Symptomatic anti-proteinuric treatment at a stable, maximum-tolerated dosage; 6. Patients with: (i) a platelet count≥ 90,000 cells/mm3; (ii) a neutrophil count ≥ 1500 cells/mm3; and (iii) appropriately monitored normal thyroid function (TSH and T4) at screening Exclusion Criteria: 1. Immunosuppressive treatment for MN in the 6 months before screening 2. Secondary MN (associated with cancer, infectious disease, autoimmune or iatrogenic disease) 3. Active nephrotic syndrome defined according to KDIGO guidelines by proteinuria \> 3.5 g/day (or 3.5 g/g urine sample) and albuminemia \< 30 g/L 4. Absence of previous immunological (anti-PLA2R1 antibodies \< 14 RU/mL in ELISA or negative indirect immunofluorescence) and clinical (partial or complete) remission 5. Patients with a history of thrombosis or treated with anticoagulants 6. Pregnancy or breastfeeding 7. Cancer in treatment 8. Pre-existing retinopathy 9. Active and severe infections 10. Severe liver failure or cirrhosis 11. Pre-existing severe heart failure 12. Pre-existing psychiatric disorder or patient at risk of anxiety or depression (HAD Score \> 11) 13. Patients who use or abuse substances 14. Hypersensitivity to active substance or excipients of study treatment